AHA/ACC/HFSA 2022: heart failure
International AHA/ACC/HFSA Current
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich PA, et al. Circulation. 2022;145:e895–e1032
DOI 10.1161/CIR.0000000000001063 · Summary checked against the source: 2026-11
At a glance
- New staging: A (at risk), B (pre-HF), C (symptomatic HF), D (advanced HF). [e904]
- LVEF categories: HFrEF ≤40%, HFmrEF 41–49%, HFpEF ≥50%, plus HFimpEF (previously ≤40%, now >40%). [e905]
- HFrEF needs four drug classes: ARNI (or ACEi/ARB), an evidence-based beta-blocker, an MRA and an SGLT2i, all Class 1. Add diuretics as needed. [e924]
- ARNI is the preferred RAS inhibitor in NYHA II–III. Switch stable patients from ACEi or ARB to ARNI. [e928]
- SGLT2i: Class 1 in HFrEF, 2a in HFmrEF and HFpEF. [e932, e948, e949]
- Keep GDMT going in HFimpEF, even if the patient is now asymptomatic. [1, B-R · e948]
- Use natriuretic peptides to diagnose and to stratify risk (Class 1). Screen at-risk patients with NP (2a). [e911]
Stages and classification
Adapted from AHA/ACC/HFSA 2022 Figure 1, Table 3 and Table 4 [e904–e905]
| Stage | Who | Key action |
|---|---|---|
| A: at risk | Hypertension, CVD, diabetes, obesity, cardiotoxic drugs, genetic cardiomyopathy or family history. No symptoms, no structural disease | Control risk factors |
| B: pre-HF | No symptoms, but structural heart disease, raised filling pressures, or raised NP/troponin | Prevent progression to symptomatic HF |
| C: symptomatic HF | Current or previous symptoms with structural disease | GDMT according to EF |
| D: advanced HF | Marked symptoms affecting daily life, repeated admissions despite optimised GDMT | Specialist care, MCS, transplant, palliative care |
| LVEF category | Criteria |
|---|---|
| HFrEF | LVEF ≤40% |
| HFimpEF | Previous LVEF ≤40% and a follow-up LVEF >40% |
| HFmrEF | LVEF 41–49% with evidence of raised LV filling pressure |
| HFpEF | LVEF ≥50% with evidence of raised LV filling pressure |
Trajectory within stage C
Patients whose symptoms resolve are still stage C. If symptoms, signs and structural abnormalities all resolve, the patient is described as HF in remission. [Figure 2 · e905]
Diagnosis
flowchart TD
A["Suspected HF<br/>history · examination · ECG · labs"] --> B["Natriuretic peptide<br/>NT-proBNP ≥125 pg/mL or BNP ≥35 pg/mL"]
B --> C["Transthoracic echocardiography<br/>(further tests if needed)"]
C --> D["HF confirmed<br/>find the cause and classify"]
D --> R["HFrEF<br/>LVEF ≤40%"]
D --> M["HFmrEF<br/>LVEF 41–49%"]
D --> P["HFpEF<br/>LVEF ≥50%"]
R --> E["Look for precipitating factors<br/>start treatment"]
M --> E
P --> E
Adapted from AHA/ACC/HFSA 2022 Figure 4 [e907]
Class 1: initial tests [e910–e911]
Class 2a
Stage A and B: prevention
Adapted from AHA/ACC/HFSA 2022 Figure 5 [e920]
| Stage A (at risk) | Recommendation | Stage B (pre-HF) | Recommendation | |
|---|---|---|---|---|
| Hypertension | Optimal BP control (1) | LVEF ≤40% | ACEi (1) | |
| Type 2 diabetes with CVD or high CV risk | SGLT2i (1) | Recent MI and LVEF ≤40% | ARB if ACEi not tolerated (1) | |
| CVD | Optimal CVD management (1) | LVEF ≤40% | Beta-blocker (1) | |
| Cardiotoxic drug exposure | Multidisciplinary evaluation (1) | LVEF ≤30%, >1 year expected survival, >40 days post-MI | ICD (1) | |
| First-degree relative with genetic cardiomyopathy | Genetic screening and counselling (1) | Non-ischaemic cardiomyopathy | Genetic counselling and testing (2a) | |
| At risk | NP screening (2a); validated risk scores (2a) |
HFrEF (stage C and D)
flowchart TD
S1["Step 1: confirm HFrEF (LVEF ≤40%), treat congestion, start GDMT<br/>ARNI (NYHA II–III) or ACEi/ARB (NYHA II–IV) · beta-blocker · MRA · SGLT2i<br/>diuretics as needed — all Class 1"] --> S2["Step 2: titrate to target doses as tolerated<br/>check labs, health status and LVEF"]
S2 --> L{"LVEF now?"}
L -- "LVEF ≤40%: persistent HFrEF" --> S3["Step 3: consider patient scenarios"]
L -- "LVEF >40%: HFimpEF" --> C["Continue GDMT"]
S3 --> H["NYHA III–IV, African American<br/>→ hydralazine + nitrate (1)"]
S3 --> I["NYHA I–III, LVEF ≤35%, >1 year survival<br/>→ ICD (1)"]
S3 --> R["NYHA II–ambulatory IV, LVEF ≤35%,<br/>sinus rhythm, LBBB with QRS ≥150 ms<br/>→ CRT-D (1)"]
S3 --> O["Consider additional therapies"]
H --> S5["Step 5: reassess symptoms, labs, health status, LVEF"]
I --> S5
R --> S5
O --> S5
S5 --> D["Refractory HF (stage D)<br/>Step 6: refer to HF specialty care<br/>durable MCS (1) · transplant (1)<br/>palliative care (1) · trials"]
S5 --> C
Adapted from AHA/ACC/HFSA 2022 Figure 6 [e924]. Step 1 drugs can be started together at low doses, or one after another; target doses don't have to be reached before the next drug is added.
Class 1, LOE A: the four pillars
- ARNI in NYHA II–III HFrEF. In stable NYHA II–III patients already on an ACEi or ARB, replace it with ARNI (1, B-R). [e928]
- ACEi if ARNI isn't feasible. ARB if ACEi causes cough or angioedema and ARNI isn't feasible. [e928]
- Beta-blocker: one of the three proven drugs (bisoprolol, carvedilol, metoprolol succinate). [e931]
- MRA (spironolactone or eplerenone) in NYHA II–IV if eGFR >30 and K⁺ <5.0. Monitor potassium and renal function closely. [e931]
- SGLT2i (dapagliflozin, empagliflozin) whether or not the patient has diabetes. [e932]
- Titrate to the trial target doses unless not tolerated (1, A). It's reasonable to adjust every 1–2 weeks (2a). [e937]
Class 1: other drugs
Class 3: harm or no benefit
- ARNI within 36 hours of the last ACEi dose, or together with an ACEi. [3: Harm, B-R · e928]
- ARNI or ACEi with any history of angioedema. [3: Harm, C-LD]
- Continuing an MRA if K⁺ can't be kept <5.5. [3: Harm, B-NR · e931]
- Non-DHP CCBs, class IC antiarrhythmics, dronedarone, thiazolidinediones, saxagliptin/alogliptin, NSAIDs in HFrEF. [3: Harm · e935]
- DHP CCBs as a treatment for HF; vitamins, supplements and hormones except to correct a deficiency. [3: No benefit · e935]
- Anticoagulation without a specific indication (AF, VTE, embolism). [3: No benefit, B-R · e934]
Drug doses
Adapted from AHA/ACC/HFSA 2022 Table 14 [e938]
| Drug | Starting dose | Target dose |
|---|---|---|
| Sacubitril/valsartan | 49/51 mg twice daily (24/26 mg twice daily possible) | 97/103 mg twice daily |
| Enalapril | 2.5 mg twice daily | 10–20 mg twice daily |
| Ramipril | 1.25–2.5 mg once daily | 10 mg once daily |
| Lisinopril | 2.5–5 mg once daily | 20–40 mg once daily |
| Losartan | 25–50 mg once daily | 50–150 mg once daily |
| Valsartan | 20–40 mg once daily | 160 mg twice daily |
| Candesartan | 4–8 mg once daily | 32 mg once daily |
| Bisoprolol | 1.25 mg once daily | 10 mg once daily |
| Carvedilol | 3.125 mg twice daily | 25–50 mg twice daily |
| Metoprolol succinate | 12.5–25 mg once daily | 200 mg once daily |
| Spironolactone | 12.5–25 mg once daily | 25–50 mg once daily |
| Eplerenone | 25 mg once daily | 50 mg once daily |
| Dapagliflozin / empagliflozin | 10 mg once daily | 10 mg once daily |
| Isosorbide dinitrate + hydralazine (fixed dose) | 20 mg + 37.5 mg three times daily | 40 mg + 75 mg three times daily |
| Ivabradine | 5 mg twice daily | 7.5 mg twice daily |
| Vericiguat | 2.5 mg once daily | 10 mg once daily |
| Digoxin | 0.125–0.25 mg daily | Serum level 0.5–<0.9 ng/mL |
Once GDMT is optimised: additional drugs
Adapted from AHA/ACC/HFSA 2022 Figure 7 [e940]
| Patient | Therapy | Class |
|---|---|---|
| NYHA II–III, sinus rhythm, HR ≥70 on maximally tolerated beta-blocker | Ivabradine | 2a |
| NYHA II–IV, LVEF <45%, recent HF admission or IV diuretics, raised NP | Vericiguat | 2b |
| Symptomatic HFrEF despite GDMT | Digoxin | 2b |
| NYHA II–IV | Omega-3 PUFA | 2b |
| Hyperkalaemia on RAAS inhibitor | Potassium binders | 2b |
Devices
flowchart TD
A["HF on GDMT >3 months (>40 days if post-MI)<br/>or special pacing indication"] --> B{"Comorbidities limit<br/>survival to <1 year?"}
B -- Yes --> N["Continue GDMT without a device"]
B -- No --> E{"LVEF?"}
E -- "36–50%" --> HB["High-degree or complete heart block<br/>→ CRT (2a)"]
E -- "≤35%" --> Q{"NYHA class / situation"}
Q -- "NYHA I" --> N1["LVEF ≤30%, ischaemic,<br/>LBBB ≥150 ms → CRT (2b)"]
Q -- "NYHA II to ambulatory IV" --> Q2["LBBB ≥150 ms → CRT (1)<br/>non-LBBB ≥150 ms → CRT (2a)<br/>LBBB 120–149 ms → CRT (2a)<br/>non-LBBB 120–149 ms → CRT (2b)"]
Q -- "Special circumstances" --> SP["AF, or sinus rhythm,<br/>with frequent or expected RV pacing<br/>→ CRT (2a)"]
Adapted from AHA/ACC/HFSA 2022 Figure 8 [e943]
Class 1: ICD for primary prevention [e941]
Class 3: no benefit [e942]
- CRT with QRS <120 ms.
- CRT in NYHA I–II with non-LBBB and QRS <150 ms.
- ICD or CRT-D when comorbidities or frailty limit survival to under 1 year.
Other procedures [Figure 9 · e944]
- Transcatheter edge-to-edge mitral repair (2a): NYHA II–IV, severe secondary MR, suitable anatomy, LVEF 20–50%, LVESD ≤70 mm, PASP ≤70 mmHg, after GDMT is optimised.
- Surgical revascularisation (1): selected patients with LVEF ≤35% and suitable coronary anatomy.
- Wireless PA pressure monitoring (2b): NYHA III with a recent admission or raised NP.
HFmrEF, HFimpEF and HFpEF
Comorbidities
Adapted from AHA/ACC/HFSA 2022 Figure 14 [e970]
| Patient | Therapy | Class |
|---|---|---|
| HF + hypertension | Treat to hypertension guideline targets; uptitrate GDMT | 1 |
| HF + type 2 diabetes | SGLT2i | 1 |
| HF + AF with CHA₂DS₂-VASc ≥2 (men) or ≥3 (women) | Anticoagulation | 1 |
| HFrEF + iron deficiency | IV iron | 2a |
| HF with symptoms from AF | AF ablation | 2a |
| AF, LVEF ≤50%, rate uncontrolled after failed rhythm control | AV node ablation + CRT | 2a |
| HF + obstructive sleep apnoea | CPAP | 2a |
Class 3: harm [e969]
Clinical pearls
- NNT for all-cause mortality over 12 months (Table 15, e939): MRA 18, beta-blocker 28, ICD 70, ARNI 80 (on top of ACEi), SGLT2i 63.
- Pre-HF (stage B) can't have symptoms, current or past. Once a patient has had symptoms, they're stage C for good, even after recovery.
- HFmrEF and HFpEF diagnoses need evidence of raised filling pressure, not just an EF number.
- Dietary sodium: just "avoid excessive intake" (2a, C-LD). There's no fixed target. [e925]
Classes and levels of evidence
How AHA/ACC/HFSA 2022 grades its recommendations. Adapted from AHA/ACC/HFSA 2022 Table 2 (updated May 2019) [e903]. Hover over any class or level cited on this page to see what it means.
| Class | Strength | Meaning | Wording used |
|---|---|---|---|
| Class 1 | Strong | Benefit >>> risk | is recommended; is indicated, useful, effective or beneficial; should be performed or administered |
| Class 2a | Moderate | Benefit >> risk | is reasonable; can be useful, effective or beneficial |
| Class 2b | Weak | Benefit ≥ risk | may or might be reasonable; may or might be considered; usefulness is unknown, unclear or uncertain |
| Class 3: No benefit | Moderate | Benefit = risk (generally used only with level A or B) | is not recommended; is not indicated, useful or effective; should not be performed or administered |
| Class 3: Harm | Strong | Risk > benefit | potentially harmful; causes harm; associated with excess morbidity or mortality; should not be performed or administered |
| Level | Meaning |
|---|---|
| Level A | High-quality evidence from more than one RCT, meta-analyses of high-quality RCTs, or one or more RCTs corroborated by high-quality registry studies |
| Level B-R (randomised) | Moderate-quality evidence from one or more RCTs, or meta-analyses of moderate-quality RCTs |
| Level B-NR (non-randomised) | Moderate-quality evidence from one or more well-designed, well-executed non-randomised, observational or registry studies, or meta-analyses of such studies |
| Level C-LD (limited data) | Randomised or non-randomised observational or registry studies with limitations of design or execution, meta-analyses of such studies, or physiological or mechanistic studies in humans |
| Level C-EO (expert opinion) | Consensus of expert opinion based on clinical experience |
Class (strength) and level (quality) are judged independently, so any class can pair with any level. A level C recommendation isn't necessarily weak: many important clinical questions can't be tested in trials, yet there may be clear clinical consensus.